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associated with systemic, even lethal manifestations, fi broblast proliferation and accumulation of acid mucopolysaccharides of the hyaluronic acid. Serum IgG class paraproteinemia is always present and it can be detected in all patients after appropriate or repeat testing (1, 2, 3) .
A case of an adult male with IgG paraproteinemia, in whom lichenoid papules evolved to scleromyxedema after two years, is reported. L ichen myxedematosus, also known as papular mucinosis, is a primary diff use cutaneous mucinosis. It is a rare cutaneous myxedematous condition characterized by formation of numerous lichenoid papules. Scleromyxedema, or ArndtGottron syndrome, is a rare, confl uent, papular and sclerotic variant of lichen myxedematosus, which is characterized by diff use thickening of the skin that underlies the papules. Th e condition is
Abstract
Lichen myxedematosus, also known as papular mucinosis, is a primary diffuse cutaneous mucinosis. It is a rare cutaneous myxedematous condition characterized by formation of numerous lichenoid papules. Scleromyxedema, also known as Arndt-Gottron syndrome, is a rare, confl uent, papular and sclerotic variant of lichen myxedematosus, characterized by diffuse thickening of the skin underlying the papules. The condition is associated with systemic, even lethal manifestations, fi broblast proliferation and accumulation of acid mucopolysaccharides of the hyaluronic acid. Serum IgG class paraproteinemia is always present and it can be detected in all patients if appropriate or even repeat testing is used. Herein, we present a 67-year-old patient with a 2-year history of skin problems. He had no health problems other than hypertension and diabetes, wich were both diagnosed 15 years before. On examination, the patient exhibited sclerodermoid lesions with diffuse pseudo-sclerodermatous thickening of the exposed skin, microstomia and sclerodactyly-like changes; on the face, there were numerous solid, shiny 2 -4 mm in diameter skin-coloured lichenoid papules, scattered across the forehead, glabellar area, nasolabial folds, perioral region, ear lobes and the neck. Histopathological examination revealed: highly distinctive collagenosis and fi brosis in the middle dermis, increased fi broblasts; collagen bundles with irregular arrangement and fragmentation; alcian blue-positive deposits with appearance consistent with acid mucins. Serum protein electrophoresis detected IgG lambda paraproteinemia. The patient was treated with systematic corticosteroids during 9 months with subsequent introduction of methotrexate and showed satisfactory results. The etiology of scleromyxedema remains unknown, since the purifi ed IgG paraprotein itself has no direct effects on fi broblast proliferation. In scleromyxedema, numerous therapeutic modalities are proposed, unfortunatelly with limited effects. In colclusion, we report a case of an adult male with lichenoid papules; after a two-year progression, they evolved into scleromyxedema and exhibited well response to conventional therapy.
A 67-year-old patient was referred with a 2-yearlong history of skin lesions that initially started on the forehead and earlobes, and then subsequently spread to the trunk and extremities. Th e patient was previously treated as an out-patient with the following diagnoses: steatocystoma multiplex< xanthelasma< erythroderma. He had no health problems other than hypertension and diabetes mellitus, wich were both diagnosed 15 years before.
On admission, the patient exhibited sclerodermoid lesions, with diff use pseudosclerodermatous thickening of the exposed skin, microstomia and sclerodactyly-like changes (Figures 1, 2, 3) , as well as elephatiasis thickening on the trunk and extremities (Figures 4, 5, 6 , 7) Th ere were numerous lichenoid, solid, hemispherical, shiny, skin-coloured papules 2 -4 mm in diameter, scattered across the forehead, glabellar area, nasolabial folds, perioral region, ear lobes, with linear distribution on the neck (Figures 8,  9 , 10).
Laboratory test results
Laboratory tests revealed the following abnormal test results: elevaed erythrocyte sedimentation rate -19, C-reactive protein -15,5 mg/L (normal range 0 -5 mg/L), fi brinogen -6,1 g/L (normal range 1,86 -3,86 g/l), glucose -9,2 mmol/L, (normal range 3,9 -6,1 mmol/l), glycated hemoglobin (HbA1c) level -9,30% (normal range 4.8 -5.9), b2 microglobulin -3,27 (normal range 0,97 -2,64 mg/l). Serum protein electrophoresis revealed "M spike" present in the lambda fraction, and immunofi xation showed IgG lambda paraprotein; urinalysis for free light chains (Bence-Jones proteins) was negative. All other fi ndings were within normal limits including the following: baseline laboratory tests such as complete blood count, 
Histopathological analysis
Histopathological analysis of skin biopsy specimens showed: profound epidermolytic hyperkeratosis in the epidermis; discrete lymphocytic perivascular infi ltrate in the upper dermis, fl attening of the epidermal dermal junction, atrophy of the adnexal structures; highly distinctive collagenosis and fi brosis; increased fi broblasts; collagen bundles exhibiting irregular arrangement and fragmentation; alcian bluepositive deposits in reticular dermis, with appearance consistent with acid mucins ( Figure 11 ). Histopathological analysis of bone marrow biopsy specimens was normal. 
Specialist consultations
Specialist consultations established the diagnosis of insulin-dependent diabetes, therefore insulin therapy was indicated.
Therapy
Apart from insulin, systemic methylpred-nisolone was initiated parenterally at a dose of 60 mg daily, with gradual dose reduction and conversion to oral therapy. Two months later, the clinical status showed considerable improvement: the number of lichenoid papules on the face ( Figure 12 ) and on the neck was reduced; elephantiasic skin folds and hyperpigmentation dramatically decreased, especially on the trunk and extremities (Figures 13,
Nailfold capillaroscopy
Nailfold capillaroscopy showed a signifi cant decrease in the number of capillaries, which were fragile and irregularly distributed but without markedly dilated capillary loops.
Radiography
Chest and esophageal passage x-ray (including barium swallow) were normal. Bone redaiographs of the hands revealed osteodegenerative changes with narrowing of the distal interphalangeal spaces.
Ultrasonography
Ultrasound of the upper abdomen revealed a cyst, 10 mm in diameter, in the right kidney. All cutaneous mucinoses are divided into primary and secondary. Primary mucinoses can be subdivided into diff use degenerative infl ammatory mucinoses, focal hamartomatous neoplastic mucinoses and 14). Th e most resistant to therapy were nasolabial folds, earlobes and hands, where induration, papules and sclerodermoid appearance were still present, but with a subjective feeling of better mobility of fi ngers. After being dismissed from the hospital, the patient was treated with prednisone tablets -30 mg per day. Six months later, due to persistent skin induration of the face, cheeks, chin and microstomy, the dose was increased to 40 mg per day and methotrexate was introduced at a weekly dose of 12,5 mg as an adjunct therapy, which resulted in marked improvement once again. systemic, even lethal, manifestations, and a localized papular, more benign form, without a demonstrable paraprotein, with 5 subtypes: 1) a discrete papular form involving any site; 2) acral persistent papular mucinosis involving only the extensor surface of the hands and wrists; 3) self-healing papular mucinosis, of a juvenile and adult type; 4) papular mucinosis of infancy, a pediatric variant of the discrete form or of acral persistent papular mucinosis; and 5) nodular form (8) . Scleromyxedema is a rare chronic cutaneous myxedematous condition of the connective tissue (1, 9, 10) which occurs in middle-aged individuals (11) , most commonly between the ages of 30 and 80, in all ethnic groups and equally in both sexes (10, 11) . Th e etiopathogenesis of scleromyxedema hasn't been fully clarifi ed. Th ere is hyperproliferation of dermal fi broblasts which produces mucin in quantities larger than normal fi broblasts, with increased collagen deposition (3) . Th e serum shows the ability to stimulate fi broblast proliferation in vitro, thus indicating the role of monoclonal paraproteinemia. Th e presence of monoclonal component (M component) or paraprotein in sera of patients with lichen myxoedematosus and scleromyxedema has been noted in nearly all cases. However, this ability of the serum remains even after the removal of IgG, which indicates that in addition to paraproteinemia, another circulatory factor is responsible. Th us, the role of serum paraproteins in scleromyxedema pathogenesis remains unknown (1, 2, 3, 12) . It has been suggested that innate altered regulation of dermal fi broblast growth might play a role in pathogenesis of sclermyxedema (3). Paraproteinemia, or monoclonal gammopathy, delineates an immunoproliferative disorder manifested by the presence of excessive amounts of one monoclonal gamma globulin in blood. Th ere are three types of paraproteins: light chain, heavy chain, and whole immunoglobulin, each of them can be present alone, or combined. Light chains can be excreted through urine, and then they are called Bence-Jones proteins. Potential causes of paraproteinemia include the following: leukemia and lymphatic myeloma (in 8.7% of the cases it is combined with multiple myeloma), plasmacytoma, or it is manifested as in our patient idiopathically as monoclonal gammopathy of unspecifi ed cause. As far follicular mucinoses. Th e group of degenerative infl ammatory mucinoses comprises several diff erent conditions, such as generalized and several localized forms of lichen myxedematosus (LM) (1).
In 1953, Montgomery and Underwood distinguished 4 types of LM: 1) generalized lichenoid eruption, later called scleromyxedema; 2) discrete papular form; 3) generalized or localized lichenoid plaque form; and 4) urticarial plaque form (6) . Th e term "scleromyxedema" was coined by Gottron in 1954 to signify the generalized lichenoid papular eruption with sclerodermoid appearance (7). In the literature, terms LM, papular mucinosis, and scleromyxedema have been often used indiscriminately as synonyms, but in 2001 based on personal experience and literature review, Rongioletti concluded that most reported cases of LM or papular mucinosis published without indication of the subtype, appeared in fact to be cases of scleromyxedema. He also recognized two clinicopathological subsets of LM, a generalized papular and a sclerodermoid form (also called scleromyxedema) with Figure 10 . Linear papules on the neck deposits, fi brosis and fi broblast proliferation; 3) monoclonal paraproteinemia; 4) absence of thyroid disease; 5) potential systematic spreading, sometimes with lethal outcome. In scleromyxedema, these characteristics represent crucial criteria in diagnosing the generalized disease (1). However, in order to diagnose localized LM, the presence of the fi rst and second of the aformentioned characteristics is required, as well as the absence of the third, fourth, and the fi fth one. Our patient met 4 of 5 aforementioned criteria: skin lesions, specifi c histologic fi ndings, monoclonal paraproteinemia and absence of thyroid disease.
Th ere is a triad of histopathologic characteristics of scleromyxedema (8, 3): 1) diff use mucin deposition in the upper and mid reticular dermis; 2) increase collagen deposition, 3) signifi cant proliferation of irregularly distributed fi broblasts. Th e epidermis may be normal or thickened due to mucin pressure and fi brosis, hair follicles may be atrophic, as in our patient; slight, perivascular, superfi cial lymphoplasmacytic infi ltrate is often present, as it was in our patient; the elastic fi bers are fragmented and decreased in number; in systematic spreading of the disease, mucin may fi ll the walls of myocardial blood vessels, as well as the interstitium of kidney, pancreas, adrenal glands and as scleromyxedema is concerned, the serum protein electrophoresis most frequently detects a monoclonal type IgG paraprotein of lambda light chain isotype, while IgA and IgM proteins are less common. Paraprotein IgG lambda, also present in our patient, has a molar eght of 110.000 daltons, whereas normal IgG weighs 160.000 daltons. Th ese fi ndings suggest that paraprotein IgG is an incomplete IgG molecule which lost a signifi cant antigen part of Fc fragment. Th e IgG of lichen myxedematosus diff eres from the IgG of multiple myeloma not only by usually showing slower electrophoretic migration, but also by the fact that its IgG molecules nearly always possess light chains of the lambda type. Th e role of the monoclonal IgG in lichen myxedematosus is not clear. Although the serum from patients with lichen myxedematosus stimulates fi broblast proliferation in vitro, the purifi ed IgG paraprotein itself has no direct eff ects on fi broblast proliferation (3).
Scleromyxedema, a generalized papular form of LM is characterized by the presence of the following criteria (13): 1) multiple cutaneous manifestations (papules, nodules, plaques) and sclerodermiform diff use thickening of the skin of the elephantiasis type; 2) specifi c histologic fi ndings, including mucin Figure 11 . Histopathological analysis of the skin biopsy specimens showed: highly distinctive collagenosis and fi brosis, as well as an increased number of fi broblasts; irregular arrangement and fragmentation of collagen bundles (HE stain, x 100) scleromyxedema, eg. hematological alterations such as eosinophilia, neurological manifestations (confusion, dysarthria, ascending paralysis, convulsions and coma; combination of high temperature, convulsions and coma), proximal myopathy, infl ammatory polyarthritis, laryngeal alterations, esophageal dysfunction, pulmonary restrictive disease, and in 10% cardial alterations (1) . Occasionally, systemic involvement may occur in other internal organs. Th ere are reports of hepatitis C virus infection (9) , bilateral scleromyxedema of the eyelids (14) , and dermatoneuro syndrome (10); malignant hematological neoplasia (multiple myeloma, acute leukemia and nerves (2) . Th e mucin present in mucinous stains: light blue in sections stained with hematoxylineosin; alcian blue at 2.5 ph but negative at 0.5 pH and shows metachromasia with toluidine blue at 7.0 pH and 4.0 pH but no metachromasia below 2.0 pH< it is PAS negative, indicating absence of neutral mucopolysacharides, and aldehyde-fuchsin negative (indicating absence of sulfated mucopolysacharides). Regular demonstration of the presence of mucin in the dermis is possible only in pretibial myxedema, in self healing-juvenile cutaneous mucinosis and in lichen myxedematosus (3) . Th ere were alcian blue positivedeposits detected in the lesions of our patient. Our patient presented without a thyroid disease, but he had diabetes mellitus and hypertension. Although no endocrine abnormalities have been found, there are numerous extracutaneous manifestations that can be present in patients with 
Conclusion
We reported a case of an adult male in whom lichenoid papules of lichen myxedematosus evolved into scleromyxedema after a two-year pregression with no extracutaneous manifestations, and good response to conventional therapy.
Abbreviations
LM -lichen myxedematosus HbA1c -glycated hemoglobin A1c ds DNA -double stranded deoxyribonucleic acid Ro/SS-A -Sjogren's Syndrome-related antigen A SS-B/La -Sjogren's Syndrome-related antigen B Scl-70 -topoisomerase 1 KPS -Karnofsky performance status T-cell lymphoma) as well as cancers, including thymic carcinoma (15) . Scleromyxedema can be clinically diff erentiated from scleroderma by the presence of papules and the absence of telangiectasias: scleromyxedema, presents with generalized eruption of papules as in lichen myxedematosus and diff use erythematous tickening of the skin which is movable over the subcutis, not bound down as in scleroderma (1, 3) .
No established standard therapy exists for systemic treatment of scleromyxedema. Various medications and methods are used with varying, mostly insuffi cient therapeutic eff ects (11) . Th ese include: topical application and intralesional injection of hyaluronidases, topical, intralesional and systemic administration of corticosteroids, radiotherapy, psoralen and ultraviolet A (PUVA) phototherapy, plasmapheresis combined with pulsed corticosteroid and/or immunosuppressive therapy, intravenous immunoglobulin combined with thalidomide, extracorporeal photochemotherapy (12, 16, 17, 18) , retinoids (11) , peripheral blood autologous stem cell transplantation (16) . Aggressive surgical interventions may be indicated for palliative care, esthetic corrections, and functional training. Melphalan, as a cytoreduction chemotherapeutic agent, has been considered as the fi rst line therapy for decades (16, 18) . Our patient was treated with systemic corticosteroids continuously during 9 months, with subsequent introduction of methotrexate. Satsifactory results have been achieved, which was also reported by other authors (19) .
Th e disease has a chronic progressive course. Spontaneous improvement is possible, but extremely rare. Th e possibility of other organs being aff ected must also be taken into consideration (11) . Th e prognosis is rather poor. Lethal outcome is also possible as a result of non-specifi c complications, but also hematological malignancy (1) . Clinical staging of scleromyxedema has been proposed as follows: 1) limited cutaneous papular mucinosis; 2) generalized cutaneous mucinosis and/or extracutaneous manifestations; 3) generalized cutaneous mucinosis and/or extracutaneous manifestations with a Karnofsky performance status less than 50% (20, 21) . Th e Karnofsky Performance Status (KPS) is a widely used method to assess the functional status of patients.
Full staging investigations should always be
